Structural basis for sulfation-dependent self-glycan recognition by the human immune-inhibitory receptor Siglec-8

JM Pröpster, F Yang, S Rabbani… - Proceedings of the …, 2016 - National Acad Sciences
JM Pröpster, F Yang, S Rabbani, B Ernst, FHT Allain, M Schubert
Proceedings of the National Academy of Sciences, 2016National Acad Sciences
Siglec-8 is a human immune-inhibitory receptor that, when engaged by specific self-glycans,
triggers eosinophil apoptosis and inhibits mast cell degranulation, providing an endogenous
mechanism to down-regulate immune responses of these central inflammatory effector cells.
Here we used solution NMR spectroscopy to dissect the fine specificity of Siglec-8 toward
different sialylated and sulfated carbohydrate ligands and determined the structure of the
Siglec-8 lectin domain in complex with its prime glycan target 6′-sulfo sialyl Lewisx. A …
Siglec-8 is a human immune-inhibitory receptor that, when engaged by specific self-glycans, triggers eosinophil apoptosis and inhibits mast cell degranulation, providing an endogenous mechanism to down-regulate immune responses of these central inflammatory effector cells. Here we used solution NMR spectroscopy to dissect the fine specificity of Siglec-8 toward different sialylated and sulfated carbohydrate ligands and determined the structure of the Siglec-8 lectin domain in complex with its prime glycan target 6′-sulfo sialyl Lewisx. A canonical motif for sialic acid recognition, extended by a secondary motif formed by unique loop regions, recognizing 6-O–sulfated galactose dictates tight specificity distinct from other Siglec family members and any other endogenous glycan recognition receptors. Structure-guided mutagenesis revealed key contacts of both interfaces to be equally essential for binding. Our work provides critical structural and mechanistic insights into how Siglec-8 selectively recognizes its glycan target, rationalizes the functional impact of site-specific glycan sulfation in modulating this lectin–glycan interaction, and will enable the rational design of Siglec-8–targeted agonists to treat eosinophil- and mast cell-related allergic and inflammatory diseases, such as asthma.
National Acad Sciences